De Western Therapeutics Institute

What De Western Therapeutics Institute does

De Western Therapeutics Institute (DWTI, 株式会社デ・ウエスタン・セラピテクス研究所) is a Nagoya-based Japanese biotechnology venture founded in 1999 and listed on the Tokyo Stock Exchange Growth Market (securities code 4576) since October 2009. The company focuses on the discovery and development of innovative therapeutics, with a strategic concentration in ophthalmology and a core technology platform centered on protein kinase inhibitors—most notably Rho-kinase inhibitors and LRRK2 multi-kinase inhibitors. Its proprietary compound library and the Drug-Western Method for target protein identification form the foundation for both internally developed candidates and in-licensed assets that are advanced, repositioned, or out-licensed.

DWTI's commercial portfolio includes GLANATEC (Ripasudil hydrochloride hydrate 0.4%), the world's first Rho-kinase inhibitor eye drop for glaucoma approved in Japan in 2014, the fixed-dose combination GLA-ALPHA launched in Japan in December 2022 and subsequently in Thailand, Malaysia, and Singapore, and DW-1002 (TissueBlue/BBG250), an ophthalmic surgical adjuvant commercialized in the US, Europe, Canada, and China via partners. The development pipeline spans H-1337 (multi-kinase LRRK2 inhibitor in late-stage glaucoma development with Glaukos), K-321 for Fuchs endothelial corneal dystrophy in global Phase III, DWR-2206 regenerative cell therapy for bullous keratopathy in Phase II, H-1129 repositioned for immune-mediated ocular surface disease, and DW-5LBT, a lidocaine patch for post-herpetic neuralgia that received US FDA approval in September 2025.

The company operates an asset-light licensing business model: it generates revenue through upfront payments, milestone payments tied to clinical and regulatory progress, and royalties on net sales of products commercialized by pharmaceutical partners including Kowa, Rohto, Wakamoto, DORC, and others. Clinical development is partially internalized through Japan Innovative Therapeutics (JIT), a consolidated subsidiary co-owned with Rohto Pharmaceutical. R&D operations are conducted at a Nagoya head office, a laboratory co-located at Mie University Faculty of Medicine, and the JIT R&D facility in Kizugawa, Kyoto, supported by industry-academia collaborations with Mie University and Kyushu University. The company has 19 employees and has historically operated at a loss, reinvesting capital into pipeline development.

Name

De Western Therapeutics Institute

Legal name

株式会社デ・ウエスタン・セラピテクス研究所

Website

https://dwti.co.jp

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

De Western Therapeutics Institute is a Nagoya-based Japanese biotech venture that discovers and develops ophthalmic and specialty therapeutics from a proprietary protein kinase inhibitor platform, generating revenue primarily through out-licensing, milestone payments, and royalties with pharmaceutical partners such as Kowa, Rohto, and DORC.

Ownership category

akta.pro rank

Headquarters

HQ city

Nagoya

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. License-Out Revenue (Licensing): DWTI develops drug candidates internally and licenses them to pharmaceutical companies. Revenue streams include: (1) Upfront/front money payments received at the time of licensing; (2) Milestone payments triggered by clinical development progress (Phase transitions, regulatory submissions, approvals); (3) Royalties as a percentage of net sales for products that reach market. This is the primary revenue model.
2. In-Licensing and Development: DWTI in-licenses compounds from external sources (e.g., DW-1001 from a UK company, DW-1002 from Helios), advances them through early development stages, and either sublicenses to partners or continues in-house development, generating milestone and royalty income.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

DWTI is a Japanese biotech venture that creates drug candidates from its proprietary protein kinase inhibitor compound library and licenses them to pharmaceutical companies at various development stages. Revenue is earned through upfront licensing payments, milestone payments tied to clinical and regulatory progress, and royalties on product sales by partners. The pipeline focuses primarily on ophthalmology (glaucoma, Fuchs endothelial corneal dystrophy, bullous keratopathy) and selected adjacent areas such as neuropathic pain.

Product overview

De Western Therapeutics Institute (DWTI) is a Japanese biotech venture specializing in drug discovery and development, primarily focused on ophthalmology. The company operates its own compound library centered on protein kinase inhibitors, including Rho-kinase and LRRK2 inhibitors. Its product portfolio includes launched products like GLANATEC® ophthalmic solution and GLA-ALPHA® combination drops for glaucoma, marketed surgical adjuvant DW-1002 (TissueBlue™), and approved neuropathic pain treatment DW-5LBT. The development pipeline features multiple candidates spanning glaucoma, Fuchs dystrophy, corneal regeneration, and other ocular diseases at various clinical stages. The company follows a licensing model, out-licensing developed compounds to pharmaceutical partners like Kowa, ROHTO, and others while retaining internal development capabilities for select products.

Differentiator

Problem solved

Functional benefit

Brands

• グラナテック®点眼液0.4%: Ripasudil hydrochloride hydrate ophthalmic solution for glaucoma treatment - first-in-class Rho kinase inhibitor eye drop
• GLANATEC® ophthalmic solution 0.4%
• グラアルファ®配合点眼液
• GLA-ALPHA® combination ophthalmic solution
• TissueBlue™

Products and services

• GLANATEC ophthalmic solution 0.4% (グラナテック®点眼液0.4%) World's first-in-class Rho-kinase inhibitor eye drop for glaucoma and ocular hypertension. Inhibits Rho-kinase to promote aqueous humor outflow via Schlemm's canal, lowering intraocular pressure. Developed and commercialized by partner Kowa; launched in Japan in December 2014.
• GLA-ALPHA combination ophthalmic solution (グラアルファ®配合点眼液) World's first fixed combination eye drop combining Ripasudil hydrochloride hydrate (Rho-kinase inhibitor) with Brimonidine tartrate for glaucoma and ocular hypertension. Improves patient adherence and quality of life by reducing the number of eye drops required. Developed and commercialized by Kowa.
• K-321 (Ripasudil for Fuchs endothelial corneal dystrophy) Rho-kinase inhibitor in development for Fuchs endothelial corneal dystrophy (FECD), a disease causing corneal edema and vision loss. In global Phase III clinical trials. Developed in partnership with Kowa.
• H-1337 Multi-kinase inhibitor (primarily LRRK2) for glaucoma and ocular hypertension, with potential applications in wet age-related macular degeneration and pulmonary hypertension. DWTI's first in-house clinical development product; completed Phase IIb in the US in 2024 and preparing for Phase III. Licensed to Glaukos Corporation in the US.
• H-1129 Rho-kinase inhibitor in development for keratoconjunctival diseases based on immune disorders. Originally developed for glaucoma (discontinued 2019), repositioned in 2025 for immune-mediated ocular surface diseases; preparing for Phase II clinical trials in Japan.
• DW-1001 In-licensed ophthalmic treatment agent using a drug repositioning approach. Phase I clinical trials completed in Japan. Licensed to Rohto Pharmaceutical for Japan.
• DW-1002 (TissueBlue) Ophthalmic surgical adjuvant containing Brilliant Blue G-250 (BBG250) dye for staining the inner limiting membrane (ILM), anterior lens capsule, and epiretinal membranes during vitreous and cataract surgery. Launched in the US, Europe, and Canada.
• DW-5LBT (MRX-5LBT) Novel lidocaine patch using MEDRx's proprietary ILTS (Ionic Liquid Transdermal System) technology for post-herpetic neuropathic pain. Received US FDA approval in September 2025. Developed jointly with MEDRx Co., Ltd.
• DWR-2206 (AE101) Regenerative cell therapy product containing cultured human corneal endothelial cells with a ROCK inhibitor for bullous keratopathy. Injected into the anterior chamber to regenerate corneal endothelium. In Phase II clinical trials in Japan, jointly developed with ActualEyes Inc.

Quantifiable outcome

• GLANATEC (Ripasudil) was the world's first Rho-kinase inhibitor eye drop for glaucoma, approved in Japan in 2014
• +5 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered new/developing, core, significant and minor.

• LAB Biotech Co., Ltd.new/developingStrategic or Co-development Partner · 1 April 2026LAB Biotech and DWTI entered into a comprehensive joint research agreement effective April 1, 2026, to develop ophthalmic therapeutic drugs using extracellular vesicles (EVs) from lactic acid bacteria (LAB). LAB Biotech contributes its lactic acid bacteria EV library and purification technology; DWTI contributes ophthalmology drug development expertise. LAB Biotech handles component analysis, quality standards, and in vitro screening; DWTI leads clinical trials, safety evaluation, and commercialization. This is an emerging area with fewer than five global studies as of March 2026.
• Kowa Co., Ltd. (興和株式会社)coreOEM/ Whitelabel/ Licensing PartnerDWTI out-licensed ripasudil hydrochloride hydrate (K-115/GLANATEC) worldwide to Kowa in 2002. Kowa developed and launched GLANATEC in Japan (2014) and continues developing K-321 (Fuchs dystrophy) and K-232 (GLA-ALPHA combination). Royalty income from Japan ended September 2024; Asian royalties continue.
• Rohto Pharmaceutical Co., Ltd. (ロート製薬株式会社)coreOEM/ Whitelabel/ Licensing PartnerDWTI licensed DW-1001 (ophthalmic treatment agent, Japan) to Rohto in December 2019. Rohto is also co-investor in Japan Innovative Therapeutics Inc. (JIT), DWTI's clinical development subsidiary, alongside DWTI.
• Wakamoto Pharmaceutical Co., Ltd. (わかもと製薬株式会社)coreOEM/ Whitelabel/ Licensing PartnerDWTI granted Wakamoto an exclusive Japanese sublicense for DW-1002 (TissueBlue) for internal limiting membrane staining applications. Wakamoto is pursuing Japanese regulatory approval.
• Dutch Ophthalmic Research Center International B.V. (DORC)coreOEM/ Whitelabel/ Licensing PartnerDWTI granted DORC an exclusive worldwide sublicense (excluding Japan) for DW-1002 (TissueBlue/BBG250) for internal limiting membrane staining, ERM staining, and related surgical applications. DORC has been commercializing the product in Europe since 2010 and in the US. Patent expiry outside US in December 2025 ended related royalties.
• Glaukos Corporation (United States)significantStrategic or Co-development PartnerDWTI signed a joint research and licensing agreement with Glaukos in August 2018 for glaucoma treatments (H-1337 and related compounds). In September 2020, the collaboration was expanded to include new disease types (corneal disorders, retinal diseases) and a new licensing agreement was signed.
• MEDRx Co., Ltd. (株式会社メドレックス)significantStrategic or Co-development PartnerDWTI and MEDRx entered a joint development agreement in April 2020 for DW-5LBT, a lidocaine patch using MEDRx's ILTS ionic liquid transdermal technology for post-herpetic neuralgia. DW-5LBT received US FDA approval in September 2025.
• ActualEyes Inc. ( акциуarize株式会社)significantStrategic or Co-development PartnerDWTI signed a joint development agreement with ActualEyes in June 2022 for DWR-2206, a regenerative cell therapy product for bullous keratopathy. ActualEyes, a Doshisha University spin-off, originally developed the technology. DWTI leads Japanese development and commercialization.
• Japan Innovative Therapeutics Inc. (日本革新創薬株式会社, JIT)coreStrategic or Co-development PartnerDWTI's consolidated subsidiary established in 2014 with joint investment from Rohto Pharmaceutical. JIT provides clinical development expertise and services, enabling DWTI to advance from early-stage discovery into clinical development internally, enhancing the group's development capability and revenue potential through expanded business domain.
• Mie University (三重大学)coreStrategic or Co-development PartnerDWTI maintains a long-standing industry-academia-government collaboration with Mie University Faculty of Medicine, established December 2006. The partnership hosts a joint research facility (臨床創薬研究学講座) at the university for drug discovery research. DWTI dispatches researchers and funds the research. This is critical infrastructure supporting DWTI's R&D activities.
• Kyushu University (九州大学)significantOEM/ Whitelabel/ Licensing PartnerDWTI acquired the BBG250 ophthalmic surgical adjuvant business from Helios in 2017 and develops the product under an exclusive license from Kyushu University, where the compound (Brilliant Blue G-250) was originally discovered by university researchers.
• Actuate Therapeutics Inc.minorStrategic or Co-development PartnerDWTI acquired the Japanese rights in June 2015 to an ophthalmic drug (DW-1001) from a British company. The British company continues to hold rights outside Japan. This in-licensing enabled DWTI to expand its pipeline with a repositioned compound.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• IVERIC bio (now Astellas): Was a US clinical-stage ophthalmology biotech focused on retinal diseases, acquired by Astellas for USD 5.9B in 2023. Represents the strategic-acquisition value-comparable for DWTI's specialty ophthalmology pipeline.
• Solasia Pharma K.K. Tokyo Stock Exchange Growth Market-listed Japanese specialty biotech with similar size, licensing business model, and clinical-stage assets. Most structurally comparable to DWTI in terms of listing tier, headcount scale, and B2B pharma-partnering GTM motion.
• Kubota Vision Inc. (formerly Acucela): US-Japan ophthalmology specialty biotech originally spun out of Japan and listed in Tokyo. Closely mirrors DWTI in Japanese origins, small size, ophthalmology focus, and clinical-stage pipeline. Eisaku Nakamura (DWTI board director) is also an Acucela alumnus.
• Senju Pharmaceutical Co., Ltd. Japanese specialty pharmaceutical company focused exclusively on ophthalmology. Directly comparable therapeutic focus to DWTI with similar niche specialization, though larger commercial presence and broader product portfolio in eye care.
• Aldeyra Therapeutics, Inc. US small-cap clinical-stage biotech focused on ophthalmology with proprietary platform technology and licensing-style business model developing novel therapies for ocular and inflammatory diseases. Comparable in scale, clinical-stage depth, and platform approach.

Emerging players

• Nicox S.A. European ophthalmology specialty biotech developing novel therapeutics with licensing partnerships. Comparable in ophthalmology focus, small-cap clinical-stage profile, and partner-led commercialization model.
• Healios K.K. Tokyo Stock Exchange Growth-listed Japanese biotech specializing in regenerative medicine and stem cell therapy. Comparable in listing tier and small-cap biotech profile, with adjacent DWR-2206 cell therapy relationship (DWTI acquired DW-1002 from Healios in 2017).

Broad incumbents

• Aerie Pharmaceuticals (now part of Alcon): Was a US specialty ophthalmology biotech focused on novel glaucoma therapies with platform pipeline. Acquired by Alcon in 2022. Represents the 'exit template' for DWTI—small-cap ophthalmology platform acquired by a strategic incumbent—and offers product-overlap comparability with DWTI's Rho-kinase glaucoma assets.
• Santen Pharmaceutical Co., Ltd. Japan's leading ophthalmology specialty pharmaceutical company. Highly comparable therapeutic-area focus with DWTI, but operates at vastly larger scale with global commercial infrastructure, broad ophthalmology portfolio, and established R&D pipeline.
• Otsuka Pharmaceutical Co., Ltd. Major Japanese pharmaceutical group with significant ophthalmology franchise. Comparable in Japanese pharma presence and potential acquirer profile, though vastly larger with broader therapeutic diversity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=LcwLkrUcyX4
• LinkedInlinkedin.com/company/dwti

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about De Western Therapeutics Institute